IL-23 and Osteoclast Formation in Arthritis
Author Information
Author(s): Yago Toru, Nanke Yuki, Kawamoto Manabu, Furuya Takefumi, Kobashigawa Tsuyoshi, Kamatani Naoyuki, Kotake Shigeru
Primary Institution: Institute of Rheumatology, Tokyo Women's Medical University
Hypothesis
IL-23 stimulates human osteoclastogenesis via IL-17 and can be targeted to treat collagen-induced arthritis.
Conclusion
The study shows that IL-23 is crucial for osteoclast formation and that blocking IL-23 can reduce inflammation and bone destruction in arthritis.
Supporting Evidence
- IL-23 directly induces osteoclastogenesis from human PBMC.
- Anti-IL-23 antibody treatment reduced paw volume in rats with collagen-induced arthritis.
- The study found that IL-17 and TNF-alpha are involved in IL-23-induced osteoclastogenesis.
Takeaway
IL-23 helps make cells that break down bone, and stopping it can help treat arthritis.
Methodology
The study involved culturing human peripheral blood mononuclear cells with IL-23 and assessing osteoclast formation, as well as treating rats with anti-IL-23 antibody to evaluate its effects on arthritis.
Potential Biases
Potential bias in the selection of animal models and the interpretation of results.
Limitations
The study had a small sample size and the effects of different dosages of anti-IL-23 antibody were not fully explored.
Participant Demographics
Healthy volunteers provided blood samples for the in vitro studies.
Statistical Information
P-Value
0.005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website